Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab vs Aducanumab in Early Alzheimer's Disease
NCT05108922Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Nov 2021; status: completed.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05108922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108922.